Jootun Ravish, Cuk Pedja, Ellebæk Mark, Andersen Per Vadgaard, Salomon Søren, Baatrup Gunnar, Al-Najami Issam, Khan Jim
Department of Colorectal Surgery, Austin hospital, Heidelberg, Victoria, Australia.
Department of Surgery, Hospital of Southern Jutland, Denmark.
Int J Surg Protoc. 2022 Feb 18;26(1):7-13. doi: 10.29337/ijsp.163. eCollection 2022.
Recent novel surgical techniques for resection of low rectal cancer have been introduced and these approaches have the potential to overcome anatomical limitations like obesity, narrow male pelvis and bulky and low tumours. Two of these procedures are robotic low anterior resection (RLAR) and transanal total mesorectal excision (TaTME).Both approaches have distinct advantages and limitations. There has been no head to head trial comparing RLAR and TaTME for patients with mid to low rectal cancer undergoing surgery by experienced surgeons. Previous studies looking at the oncological outcomes of either TaTME or robotic TME included many centres where the surgeons were on a learning curve and hence the true oncological outcomes and clinical benefits can not be measured accurately.
The inclusion criteria include experienced surgeons defined as minimum of 60 prior procedures with RLAR or TaTME. Successful oncological and clinical outcomes are defined as circumferential resection margin (CRM) ≥1 mm with limited postoperative morbidity (absence of Clavien-Dindo grade III-IV complications within 30 days after surgery). Local and distal recurrence rates with DFS over 3 years will be measured as primary outcome.Data will be collected prospectively and entered in a dedicated database.
The primary objective of this study is to conduct a multicentre prospective trial to investigate clinical outcomes, in particular disease free survival (DFS) in patients undergoing RLAR and TaTME. The additional goal is to investigate other efficacy measures, complications rates, health economic aspects and patient reported health related quality of life.This paper describes an important trial conducted in expert centres to establish the needed knowledge for a detailed comparison of outcomes for TaTME versus RLAR.This trial is the first comparative study, comparing TaTME and RLAR, seeking to establish foothold for tailor-made surgical treatment of low rectal cancer patients.
The trial is registered in September 2019. id: NCT04200027.
近期已引入用于低位直肠癌切除的新型手术技术,这些方法有可能克服诸如肥胖、男性骨盆狭窄以及肿瘤体积大且位置低等解剖学限制。其中两种手术是机器人辅助低位前切除术(RLAR)和经肛门全直肠系膜切除术(TaTME)。这两种方法都有各自独特的优点和局限性。对于由经验丰富的外科医生进行手术的中低位直肠癌患者,尚未有比较RLAR和TaTME的直接对比试验。先前关于TaTME或机器人全直肠系膜切除术肿瘤学结果的研究涉及许多外科医生仍处于学习曲线阶段的中心,因此无法准确衡量真正的肿瘤学结果和临床益处。
纳入标准包括定义为至少有60例先前RLAR或TaTME手术经验的经验丰富的外科医生。成功的肿瘤学和临床结果定义为环周切缘(CRM)≥1mm且术后发病率有限(术后30天内无Clavien-Dindo III-IV级并发症)。将3年DFS的局部和远处复发率作为主要结局进行测量。数据将前瞻性收集并录入专用数据库。
本研究的主要目的是进行一项多中心前瞻性试验,以调查接受RLAR和TaTME的患者的临床结局,特别是无病生存期(DFS)。额外目标是调查其他疗效指标、并发症发生率、卫生经济学方面以及患者报告的与健康相关的生活质量。本文描述了在专家中心进行的一项重要试验,以建立对TaTME与RLAR结局进行详细比较所需的知识。该试验是第一项比较TaTME和RLAR的对比研究,旨在为低位直肠癌患者的定制手术治疗奠定基础。
该试验于2019年9月注册。编号:NCT04200027。